# US 2012/0251558 A1 · Antibody-drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251558 A1
- Document ID: US20120251558A1
- Status: Published application
- Kind: A1
- Application number: 13/435,731
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Wyeth
- Inventors: Hans-Peter Gerber; John Francis DiJoseph; Kiran Manohar Khandke; Kimberly Ann Marquette; Puja Sapra; Lioudmila Gennadievna Tchistiakova
- Web page: https://patentgrep.com/patent/US20120251558A1

## CPC

- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/68031: {the drug being an auristatin}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.

## Claims

### Claim 1

An antibody-drug conjugate of the formula:
Ab-(LU-D)p
or a pharmaceutically acceptable salt thereof wherein;
(a) Ab is an anti-5T4 antibody or antigen binding portion thereof, comprising:
(i) a VH CDR1 region as shown in SEQ ID NO: 5,
(ii) a VH CDR2 region as shown in SEQ ID NO: 6,
(iii) a VH CDR3 region as shown in SEQ ID NO: 7;
(iv) a VL CDR1 region as shown in SEQ ID NO: 8,
(v) a VL CDR2 region as shown in SEQ ID NO: 9, and
(vi) a VL CDR3 region as shown in SEQ ID NO: 10,
(b) LU is a linker unit selected from the group consisting of maleimidocaproyl and maleimidocaproyl-Val-Cit,
(c) p is an integer from about 1 to about 8, and
(d) D is a Drug unit selected from the group consisting of MMAE, MMAD, and MMAF.

### Claim 2 (depends on 1)

The antibody-drug conjugate of claim 1 wherein said anti-5T4 antibody or antigen binding portion thereof, comprises the VH region of SEQ ID NO: 3 and the VL region of SEQ ID NO: 4.

### Claim 3 (depends on 2)

The antibody-drug conjugate of claim 2 wherein said anti-5T4 antibody or antigen binding portion thereof, consists of a heavy chain having SEQ ID NO:1 and a light chain having SEQ ID NO: 2.

### Claim 4 (depends on 3)

The antibody-drug conjugate of claim 3, wherein said antibody or antigen binding portion thereof, recognizes an epitope on human 5T4 antigen, wherein said epitope comprises amino acid residues 173-258 and 282-361 of the amino acid sequence of SEQ ID NO:11.

### Claim 5 (depends on 1)

The antibody-drug conjugate of claim 1 wherein:
(a) said anti-5T4 antibody consists of a heavy chain having SEQ ID NO:1 and a light chain having SEQ ID NO: 2,
(b) said LU is maleimidocaproyl,
(c) said Drug is MMAF, and
(d) p is 4.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the antibody-drug conjugate of claim 1 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

A method of treating 5T4-positive cancer in a patient in need thereof, comprising administering to said patient the antibody-drug conjugate according to claim 1.

### Claim 8 (depends on 7)

The method of claim 7 wherein said cancer is selected from the group consisting of colorectal, breast, pancreatic, and non-small cell lung carcinomas.
